Syros Pharmaceuticals shares are trading lower after the company announced it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial.
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals shares are trading lower after the company announced it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial.
August 13, 2024 | 10:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Syros Pharmaceuticals shares are trading lower after the company announced it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial.
The discontinuation of the SELECT-AML-1 Phase 2 clinical trial is a significant setback for Syros Pharmaceuticals, likely leading to a negative short-term impact on the stock price as investors react to the halted progress in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100